Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer

Clinical Cancer Research

Volumn 8, Issue 3, 2002, Pages 679-683

  Morris, Michael J ^a,b   Tong, William P ^a,b   Cordon Cardo, Carlos ^a,b   Drobnjak, Marija ^a,b   Kelly, William K ^a,b   Slovin, Susan F ^a,b   Terry, Kathryn L ^a   Siedlecki, Karen ^a   Swanson, Paul ^a,b   Rafi, Mohmed ^c   DiPaola, Robert S ^c   Rosen, Neal ^a,b   Scher, Howard I ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; OBLIMERSEN;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE PAIN; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERABILITY; DYSPNEA; FATIGUE; HEART PALPITATION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERGLYCEMIA; INFECTION; LIVER TOXICITY; MONONUCLEAR CELL; NUCLEOTIDE METABOLISM; PERIPHERAL LYMPHOCYTE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RASH; STEADY STATE; THROMBOCYTOPENIA; THROMBOSIS; TRANSAMINITIS; URINE RETENTION; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; BLOTTING, WESTERN; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; GENES, BCL-2; HALF-LIFE; HUMANS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; NEOPLASMS; OLIGONUCLEOTIDES, ANTISENSE; PROTO-ONCOGENE PROTEINS C-BCL-2; SAFETY; THIONUCLEOTIDES; TRANSAMINASES;

EID: 0036303535     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death
2. The bcl-2 candidate proto-oncogene product is a 24-kilodalton integral-membrane protein highly expressed in lymphoid cell lines and lymphomas carrying the t(14;18) translocation
3. Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma
4. Bcl-2 gene promotes hematopoietic cell survival and cooperates with c-myc to immortalize pre-B cells
5. Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers
6. Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone refractory human prostate cancers
7. Prognostic significance of bcl-2 in clinically localized prostate cancer
8. Histochemical detection of intranuclear DNA fragmentation and its relation to the expression of bcl-2 oncoprotein in human prostatic cancer
9. Expression of the proto-oncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer
10. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo
11. Bcl-2 protein in non-small-cell lung carcinoma
12. Prognostic value of the expression of p53, bcl-2, and bax oncoproteins, and neovascularization in patients with radically resected non-small-cell lung cancer
13. Bcl-2 protein expression in cutaneous malignant melanoma and benign melanocytic nevi
14. Bcl-2 in normal human breast and carcinoma, association with estrogen receptor-positive, epidermal growth factor receptor-negative tumors in situ cancer
15. Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers
16. Patterns of Bcl2 expression in pT3 primary and metastatic renal cell carcinoma (Abstract 1330)
17. Expression of bcl-2, bcl-x, bax, and bak in renal parenchyma, oncocytomas, and renal cell carcinomas
18. Apoptosis and expression of the bcl-2 proto-oncogene in the fetal and adult human kidney: Evidence for the contribution of bcl-2 expression to renal carcinogenesis
19. Bcl-2: Prevention of apoptosis as a mechanism of drug resistance
20. Interactions among members of the bcl-2 protein family analyzed with a yeast two-hybrid system
21. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death
22. Bad: A heterodimeric partner for bcl-XL and bcl-2, displaces bax and promotes cell death
23. Dysregulation of apoptosis in cancer
24. Regulation of apoptosis by bcl-2 family proteins and its role in cancer and chemoresistance
25. Bcl-2 and the regulation of programmed cell death
26. Targeting bcl-2 gene to delay androgen-independent progression and enhance chemosensitivity in prostate cancer using antisense bcl-2 oligodeoxynucleotides
27. Tumor regression of human breast carcinomas by combination therapy of anti-bcl-2 antisense oligonucleotide and chemotherapeutic drugs
28. Bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice
29. Phase I clinical and pharmacokinetic study of Bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin’s lymphoma
30. Pharmacokinetics of G3139, a phosphorothioate oligodeoxynucleotide antisense to bcl-2, after intravenous administration or continuous subcutaneous infusion to mice
31. Phase I trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer
32. Phase I study of an antisense oligonucleotide to protein kinase c-a (ISIS 3521/CGP 64128A) in patients with cancer
33. A phase I trial of H-ras antisense oligonucleotide ISIS 2503 administered as a continuous intravenous infusion in patients with advanced carcinoma
34. Clinical pharmacokinetics and pharmacodynamics of G3139 (Genta Incorporated) antisense oligonucleotide targeting BCL-2
35. Chemosensitization of malignant melanoma by BCL2 antisense therapy